Healthpeak Properties Receives Higher Price Target From UBS Following Q3 Earnings
UBS boosted its valuation target for Healthpeak Properties to USD 22 while keeping a neutral rating, following third-quarter results and revised full-year earnings guidance.
UBS lifted its target price on shares of Healthpeak Properties to USD 22 from an earlier USD 20, according to a report published via MarketScreener. The investment bank maintained its neutral stance on the real estate investment trust, offering a more positive valuation marker without giving the stock an outright bullish endorsement. On European exchange Lang & Schwarz, shares changed hands at 18.42 euros late Wednesday evening, November 11, 2026.
The analyst revision comes shortly after Healthpeak announced financial results for the third quarter of 2026. The trust recorded revenue of US$820.89 million and generated net income of US$17.26 million. Net income over the initial nine months reached US$263.71 million. Diluted earnings per share from continuing operations remained in positive territory, recovering from a net loss registered during the corresponding period in 2025.
Alongside its quarterly results, the company trimmed its full-year 2026 guidance for diluted earnings per share to a span of US$0.39 to US$0.41. The revision was largely caused by expanded depreciation and amortization linked to properties acquired under the Janus Living senior housing brand, rather than a decline in core everyday property operations.
Healthpeak's longer-term trajectory carries mixed outlooks among equity analysts. Figures compiled by Simply Wall St note that the firm generated US$242.7 million in current earnings, with consensus estimates pointing to annual revenue expansion of 6.7%. However, analysts model revenue reaching US$3.6b and net earnings dropping to US$145.5 million by 2029, representing an estimated decrease of roughly US$97 million. Earlier optimistic projections that emphasized Janus Living as a growth catalyst had anticipated up to US$4.0b in revenue and US$220.7 million in earnings by 2029.
The company's shares last closed at $20.26, while Simply Wall St calculated an intrinsic fair value mark of $22.61 using an 8.2% discount rate. The stock carries a price-to-earnings ratio of 37x, compared to a global healthcare REIT sector average of 18.2x. Over the trailing year, the trust has recorded a total shareholder return of 22.3%, contrasting with a 21.5% decline over a five-year window.